


PLANT ANTIMUTAGENS, 6.¹ INTRICATIN AND INTRICATINOL,
NEW ANTIMUTAGENIC HOMOISOF flavONOIDS FROM
*HOFFMANOSSEGIA INTRICATA*MONROE E. WALL,* MANSUKH C. WANI,* G. MANIKUMAR,
HAROLD TAYLOR, and ROBERT MCGIVNEYResearch Triangle Institute, P.O. Box 12194,
Research Triangle Park, North Carolina 27709

ABSTRACT.—Intricatin [**1**] and intricatinol [**2**] are new homoisoflavonoids isolated from a desert plant *Hoffmanossegia intricata*, which was collected in Baja California, Mexico. The structures of the compounds were elucidated using a variety of spectroscopic techniques. The structure of **1** was shown to be 7,4'-dimethoxy-8-hydroxyhomoisoflavone, and **2** was shown to be 4'-methoxy-7,8-dihydroxyhomoisoflavone. Both compounds **1** and **2** displayed activity in the inhibition of the mutagenicity of 2AN toward *Salmonella typhimurium* (T98). Compound **2** was much more active than **1** in the case of the inhibition of the mutagenicity of AAF toward *S. typhimurium* (T98) and the inhibition of EMS towards *S. typhimurium* (T100). Compounds **1** and **2** are the first examples of antimutagenic activity in homoisoflavones.

Two new closely related homoisoflavonoids, intricatin [**1**] and intricatinol [**2**], have been isolated from the roots of *Hoffmanossegia intricata* Brandege (Fabaceae), guided by the inhibition of the mutagenicity of 2-aminoanthracene (2AN) toward *Salmonella typhimurium* (T-98) by crude and purified extracts and concentrates (1-5). Homoisoflavonoids, with one exception, have previously been reported to occur only in plants which are members of the Liliaceae family (6-10). This paper reports the characterization and antimutagenic or toxic properties of new homoisoflavones **1** and **2** isolated from a nonrelated family, Fabaceae.



- 1** R = Me
2 R = H

EXPERIMENTAL

ANTIMUTAGENIC TESTING.—The procedures for determining the inhibition of the mutagenicity of 2AN toward cultures of *S. typhimurium* (T-98) by crude plant extracts or purified products and toxicity determinations have been described in previous papers (1-5). Assays for antimutagenicity of pure compounds toward 2AN and acetylaminofluorene (AAF), which require metabolic activation, and ethyl methanesulfonate (EMS), which does not, have also been described (1-5).

GENERAL ISOLATION AND CHARACTERIZATION METHODS.—Melting points were determined on a Kofler hotstage microscope and are uncorrected. ¹H- and ¹³C-nmr spectra were obtained with a Bruker WM250 spectrometer using TMS as an internal standard and CDCl₃ as a solvent. High resolution mass spectra were obtained with an AEI MS-902 instrument. Uv spectra were obtained in MeOH with a Varian 2290-UV-VIS spectrometer and ir spectra with Perkin-Elmer 467 Grating spectrometer. Standard chromatography was carried out on Si gel E. Merck 230-40 mesh or Baker Flash chromatography Si gel using, in general, CH₂Cl₂ as eluent with a gradient of 0.5-10.0% MeOH. For tlc determinations precoated Si gel plates were utilized; normal phase EM precoated Si gel 60, F254, usual solvent 10% MeOH in

¹For Part 5 of this series, see Manikumar *et al.* (5).

CH₂Cl₂; reversed-phase, Baker precoated Si gel C₁₈-F plates, usual developer 5–10% H₂O in MeOH. Exposure of plates to iodine vapor was used as a general detection agent; alternatively, spraying with phosphomolybdate reagent followed by heating was utilized.

PLANT MATERIALS.—Roots of *H. intricata* were collected in March 1980, in Baja California, Mexico, by Richard Spjut, Plant Medicinal Resources Laboratory ARS. A voucher specimen is deposited in the herbarium of the National Arboretum, ARS.

EXTRACTION AND ISOLATION.—Roots (0.2 kg) were extracted with hot 95% EtOH. The EtOH extract was concentrated and the residue partitioned between H₂O and CHCl₃. After concentration of the CHCl₃ fraction, the crude residue (8.7 g) was tested for inhibition of 2AN mutagenicity at 0.6 mg/plate. Two separate assays showed inhibition of 38 and 50%. The CHCl₃ residue was nontoxic at 0.6 mg/plate. The CHCl₃ residue (4.0 g) was chromatographed on 50 g of Baker Si gel and was eluted initially with 0.5% MeOH in CH₂Cl₂ (fractions 1–50). Fractions 30–50 yielded inhibitory material (0.3 g). Further elution with 2% MeOH in CH₂Cl₂ yielded inhibitory material (0.06 g) in fractions 76–120. The material from fractions 30–50 was crystallized from aqueous MeOH, yielding 0.044 g of yellow crystals of a new compound designated intricatin [**1**] (7,4'-dimethoxy-8-hydroxyhomoisoﬂavone), 62% inhibition of 2AN at 0.3 mg/plate, nontoxic at 0.6 and 0.3 mg/plate. The more polar fraction was crystallized from aqueous MeOH, yielding 0.12 g of yellow needles of a new compound designated intricatinol [**2**] (4'-methoxy-7,8-dihydroxyhomoisoﬂavone), toxic at 0.6 mg, nontoxic at 0.3 mg/plate, 87% inhibition of 2AN at 0.3 mg/plate.

Intricatin [**1**].—Mp 157–159°, uv λ max (MeOH) nm (log ϵ) 347 (4.41), 237 sh (4.27), (MeOH + NaOH) 393 (4.48), 324 (4.20), 269 (3.99); ir ν max (CHCl₃) 3510 (OH), 1660 (C=O), 1600 (aromatic), 1470, 1300, 1175, 840, 820 cm⁻¹; ¹H nmr (Me₂CO-*d*₆) δ 3.82 (3H, s, OMe), 3.88 (3H, s, OMe), 5.48 (2H, d, *J* = 2 Hz, H-2), 6.65 (1H, d, *J* = 8.8 Hz, H-6), 7.06 (2H, d, *J* = 8.8 Hz, H-3', -5'), 7.43 (2H, d, *J* = 8.8 Hz, H-2', -6'), 7.61 (1H, d, *J* = 8.8 Hz, H-5), 7.72 (1H, broad triplet, H-9); hrms *m/z* (rel. int. %) [**M**]⁺ 312.0990 (C₁₈H₁₆O₅ = 312.0998) (100), 297 (15), 167 (55), 146 (70), 121 (35).

Intricatinol [**2**].—Mp 196–198°, uv λ max (MeOH) nm (log ϵ) 351 (4.44), 234 sh (4.24), (MeOH + NaOH) 396 (4.33), 320 (4.17), 286 (3.93); ir ν max (KBr) 3375, 1660, 1600, 1270, 840, 815 cm⁻¹; ¹H-nmr (DMSO-*d*₆) 2 broad OH peaks at δ 10.0 and δ 8.7 exchanged with D₂O, 3.83 (3H, s, OMe), 5.39 (2H, d, *J* = 2 Hz, H-2), 6.57 (1H, d, *J* = 8.5 Hz, H-6), 7.06 (2H, d, *J* = 8.5 Hz, H-3', -5'), 7.27 (1H, d, *J* = 8.5 Hz, H-5), 7.42 (2H, d, *J* = 8.5 Hz, H-2', -6'), 7.65 (1H, broad s, H-9); hrms *m/z* (rel. int. %) [**M**]⁺ 298.0845 (C₁₇H₁₄O₅ = 298.0841) (30), 153 (65), 152 (40), 146 (100).

RESULTS AND DISCUSSION

The uv and ir spectra of intricatin [**1**] and intricatinol [**2**] are similar to those described for the structurally similar homoisoﬂavones bonducellin (9) and 8-methoxybonducellin (10). Hrms of **1** gave a molecular formula of C₁₈H₁₆O₅ in accord with the assigned structure. Ions at *m/z* 312 [**M**]⁺, 297 [**M** - 15]⁺, and 281 [**M** - 31]⁺ are characteristic. Of greater diagnostic value, however, was a strong fragment peak at *m/z* 167 indicative of retro-Diels-Alder rearrangement with one OH and one OMe moiety in ring A (11). Hence, the remaining OMe group must be in ring B.

The ¹H-nmr spectrum at 250 MHz (Me₂CO-*d*₆) revealed the presence of two methoxy groups with signals at δ 3.88 and δ 3.82. One methoxy group was assigned to the 4' position in agreement with literature (6–10) and the other to ring A based on the mass spectral fragmentation pattern (11). A perturbed AA', BB' system had two protons centered at δ 7.43 and two at δ 7.06 which were assigned to H-2', -6' and H-3', -5', respectively, similar to the data reported for bonducellin (9,10). The spectra showed two ortho coupled protons (*J* = 8.5 Hz) at δ 7.61 and δ 6.65 assignable to H-5 and H-6, respectively. A proton due to H-9 appeared at δ 7.72 as a broad triplet as a result of coupling with the two methylenic protons at position 2, which appeared as a doublet at δ 5.48 (*J* = 2 Hz). The position of the H-9 proton is indicative of a trans double bond at this position (6). In CDCl₃, a D₂O exchangeable proton (8-OH) appeared at δ 6.3. The location of the methoxy groups at C-7 and C-4' was deduced from the C₆H₆-induced shifts of methoxy groups. Only methoxy groups ortho to an aromatic proton are shifted upfield by 0.5 ppm in C₆D₆ compared to CDCl₃ (12). We found both




FIGURE 1. Long range 2D proton correlation (COSYLR) of intricatinol [2].

methoxy groups at C-7 and C-4' shifted upfield by 0.5–0.6 ppm, confirming the structure of **1** as 7,4'-dimethoxy-8-hydroxyhomoisoflavone.

The uv and ir spectra of **2** closely resembled those of **1** and 8-methoxybonducellin (10). Hrms showed that the molecular formula of **2** was C₁₇H₁₄O₅. A strong fragment of *m/z* 153 was indicative of a retro-Diels-Alder rearrangement with two OH moieties in ring A (11).

The nmr spectrum (250 MHz) of **2** in DMSO-*d*₆ revealed the presence of one methoxy group at δ 3.83 assigned to the C-4' position and two D₂O exchangeable hydroxyl groups at δ 10.0 and 8.7. A perturbed AA', BB' system had two protons centered at δ 7.42 and two at δ 7.06 which were assigned to the 2', 6' and 3', 5' positions, respectively. There were two ortho coupled protons ($J = 8.5$ Hz) centered at δ 7.27 and δ 6.57. These signals corresponded to H-5 and H-6, respectively. The two aliphatic protons at position 2 appeared as a narrow doublet at δ 5.39 ($J = 2$ Hz), and H-9 appeared at δ 7.65. The relationship of H-2 and H-9 protons was confirmed by long range 2D-proton correlation spectra (COSYLR) (Figure 1). Hence the structure of **2** is 7,8-dihydroxy-4'-methoxyhomoisoflavone.

Intricatin [**1**] was nontoxic at 0.6 and 0.3 mg/plate; intricatinol [**2**] was toxic at 0.6 mg but nontoxic at 0.3 mg/plate. Table 1 shows the inhibition by **1** and **2** of the mutagenicity toward of *S. typhimurium* of 2AN, AAF, and EMS. The first two require metabolic activation but the latter is a direct acting mutagen which is known to alkylate the various DNA bases (13). Compound **1** was active in the inhibition of the mutagenicity of 2AN toward *S. typhimurium* (T98) but did not inhibit the mutagenicity of AAF, *S. typhimurium* (T98), or EMS, *S. typhimurium* (T100). The lack of dose response for **1** shown in Table 1 at doses of 300–37.5 μ g is anomalous; usually a dose response is observed over this dose range (cf. Table 1, compound **2**). Compound **1** was inactive in inhibition of the mutagenicity of AAF toward *S. typhimurium*. The dihydroxy analogue **2** was in general more broadly active than **1** in the inhibition of the mutagenicity of 2AN, AAF, and EMS (Table 1). The greater potency of **2** may be due to the presence of a dihydroxy moiety in ring A. In a previous study with flavonoids (2), we found that hydroxylated flavonoids were generally more active than their methylated analogues.

TABLE 1. Inhibition of Mutagenicity of Various Mutagens by Intricatin [**1**] and Intricatinol [**2**].

Compound	Mutagen ^a								
	2AN ^{a,b}			AAF ^{a,b}			EMS ^a		
	Positive Control 2.5 μ g/plate 1794 Colonies/plate ^c			Positive Control 25 μ g/plate 1131 Colonies/plate ^c			Positive Control 750 μ g/plate 2046 Colonies/plate ^c		
	Dose μ g/plate	Colonies ^c #/plate	Inhibition ^d %	Dose μ g/plate	Colonies ^c #/plate	Inhibition %	Dose μ g/plate	Colonies ^c #/plate	Inhibition %
1	300	673	62	300	1047	7	300	1126	45
	150	279	84	150	1341	0	150	1491	27
	75	151	92	75	1162	0	75	1966	4
	37.5	543	70	37.5	1035	8	37.5	1854	9
2	300	226	87	300	335	70	300	526	74
	150	773	57	150	518	54	150	363	82
	75	1141	36	75	590	48	75	537	74
	37.5	1654	8	37.5	840	26	37.5	1438	30

^a2AN = 2-aminoanthracene; AAF = acetylaminofluorene; EMS = ethyl methanesulfonate.

^bRequires metabolic activation.

^cAverage of 3 plates.

^d% Inhibition = $\frac{\text{Colonies in positive control} - \text{Colonies in experimental plate}}{\text{Colonies in positive control}} \times 100$.

ACKNOWLEDGMENTS

We thank Thomas Hughes, Janet Warner, and Kevan Gaetano for advice and technical assistance.

LITERATURE CITED

1. M.E. Wall, M.C. Wani, T.J. Hughes, and H. Taylor, *J. Nat. Prod.*, **51**, 866 (1988).
2. M.E. Wall, M.C. Wani, G. Manikumar, P. Abraham, H. Taylor, T.J. Hughes, J. Warner, and R. McGivney, *J. Nat. Prod.*, **51**, 1084 (1988).
3. M.E. Wall, M.C. Wani, G. Manikumar, T.J. Hughes, H. Taylor, R. McGivney, and J. Warner, *J. Nat. Prod.*, **51**, 1148 (1988).
4. M.E. Wall, M.C. Wani, K. Gaetano, G. Manikumar, H. Taylor, and R. McGivney, *J. Nat. Prod.*, **51**, 1226 (1988).
5. G. Manikumar, K. Gaetano, M.C. Wani, H. Taylor, T.J. Hughes, J. Warner, R. McGivney, and M.E. Wall, *J. Nat. Prod.*, **51**, 769 (1989).
6. P. Bohler and Ch. Tamm, *Tetrahedron Lett.*, 3479 (1967).
7. T.M. Dewick, *Phytochemistry*, **14**, 983 (1975).
8. W.T.L. Sidwell and Ch. Tamm, *Tetrahedron Lett.*, 475 (1970).
9. K.K. Purushothaman, K. Kalyani, K. Subramaniam, and S.P. Shanmughanathan, *Indian J. Chem.*, **21B**, 383 (1982).
10. D.D. McPherson, G.A. Cordell, D.D. Soejarto, J.M. Pezzuto, and H.S. Fong, *Phytochemistry*, **22**, 2835 (1983).
11. T.J. Mabry and K.R. Markham, in: "The Flavonoids." Ed. by J.B. Harborne and H. Mabry, Academic Press, New York, 1975, Part 1, pp. 78-126.
12. A. Peter and P.I. Amenechi, *J. Chem. Soc. C*, 887 (1969).
13. G.A. Saga, *Mutat. Res.*, **134**, 113 (1984).

Received 6 February 1989